DAX21.787 -0,5%ESt505.325 -0,6%Top 10 Crypto15,00 +3,5%Dow44.338 -0,9%Nas19.517 -1,4%Bitcoin94.324 +1,4%Euro1,0332 -0,5%Öl74,67 +0,5%Gold2.862 +0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Amazon 906866 Palantir A2QA4J BYD A0M4W9 Porsche PAG911 BASF BASF11 Infineon 623100 Tesla A1CX3T Siemens Energy ENER6Y Deutsche Telekom 555750 Lufthansa 823212 Bayer BAY001 Volkswagen (VW) vz. 766403 Commerzbank CBK100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Börsen vor dem Wochenende im Minus -- DAX geht nach Rekordhoch schwächer ins Wochenende -- Amazon enttäuscht mit Prognose -- Milliardenauftrag für Rheinmetall -- Pinterest, NVIDIA, L'Oréal im Fokus
Top News
Börse New York: S&P 500 am Nachmittag mit Abgaben Börse New York: S&P 500 am Nachmittag mit Abgaben
Dow Jones-Handel aktuell: Dow Jones sackt ab Dow Jones-Handel aktuell: Dow Jones sackt ab
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Sanofi Aktie

NeuKaufenVerkaufen
Sanofi Aktien-Sparplan
103,64 EUR +1,12 EUR +1,09 %
STU
103,26 EUR -0,76 EUR -0,73 %
GVIE
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.129,42 Mrd. EUR

KGV20,42

WKN920657

ISINFR0000120578

SymbolSNYNF

Sanofi Aktien News

DatumMeistgelesen
GlobeNewswirePress Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics
GlobeNewswirePress Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
GlobeNewswirePress Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
GlobeNewswirePress Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology
GlobeNewswirePress Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this seri
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - October 2023
PR NewswireSanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.
GlobeNewswirePress Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
GlobeNewswirePress Release: Sanofi Enters Next Chapter of Play to Win Strategy
GlobeNewswirePress Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
GlobeNewswirePress Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio
GlobeNewswirePress Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously publishe
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - September 2023
GlobeNewswirePress Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
GlobeNewswirePress Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
GlobeNewswirePress Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
GlobeNewswirePress Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
GlobeNewswirePress Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
GlobeNewswirePress Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A
GlobeNewswirePress Release: Availability of the Q3 2023 Memorandum for modelling purposes
GlobeNewswirePress Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change
PR NewswireSanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - August 2023
GlobeNewswirePress Release: Sanofi announces changes to its Executive Committee
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - July 2023
GlobeNewswirePress Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
GlobeNewswirePress release: Online availability of Sanofi’s half-year financial report for 2023
GlobeNewswirePress Release: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment
GlobeNewswirePress Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised
PR NewswireSanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares – June 2023
GlobeNewswirePress Release: FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
GlobeNewswirePress Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
GlobeNewswirePress Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody
GlobeNewswirePress Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing
GlobeNewswirePress Release: Availability of the Q2 2023 Memorandum for modelling purposes
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - May 2023
GlobeNewswirePress Release: Sanofi prevails in Zantac arbitration initiated by Boehringer Ingelheim
GlobeNewswirePress Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients
GlobeNewswirePress Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants
Wer­bung

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.